Search results
Dec 7, 2021 · Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an...
Jun 29, 2023 · Eli Lilly has reached a deal to acquire Emergence Therapeutics, a German biotechnology startup focused on antibody-drug conjugates, or ADCs, the company confirmed to BioPharma Dive on Thursday.
Jul 3, 2023 · Eli Lilly has acquired European startup Emergence Therapeutics, a biotech focused on developing antibody-drug conjugates (ADCs) for cancers with high unmet need. The most advanced candidate in Emergence’s pipeline is ETx-22, an ADC targeting Nectin-4, a protein found on malignant cells.
Sep 6, 2022 · In addition to GlycoConnect™ and HydraSpace™ technology, the toxSYN™ linker-payload platform rounds out a fully complementary technology platform that enables any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.
Jun 29, 2023 · The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs as well as in third-party collaborations. The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma.
- Eli Lilly (Group)
- Emergence Therapeutics AG
- Eli Lilly & Co. Inc. (NYSE: LLY)
- 2023-06-29
Oct 21, 2021 · Emergence Therapeutics obtains the rights to develop a novel antibody-drug conjugate using Mablink Bioscience’s PSARlink™ drug-linker technology.
People also ask
Who is emergence Therapeutics?
Where is emergent based?
Is Eli Lilly acquiring emergence Therapeutics?
Why did emergence Therapeutics invest in an oversubscribed ADC round?
Who owns emergence Therapeutics & sigilon Therapeutics?
Will emergence Therapeutics raise €87 million Series A financing for nectin-4 ADC?
Synaffix B.V. (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a licensing agreement of up to $360 million, providing Emergence access on a target-specific basis to Synaffix’s proprietary antibody drug conjugate (ADC) technologies comprising GlycoConnect ...
